All SARS-CoV-2 / COVID-19 at the Institut Pasteur

An epidemic of pneumonia of viral appearance and of unknown etiology emerged in the city of Wuhan (Hubei province, China) in December 2019. On January 9, 2020, the discovery of a new coronavirus (first called 2019-nCoV, then SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). This coronavirus is the agent responsible for the new infectious respiratory disease called Covid-19 (CoronaVIrus Disease 2019).

RESEARCH PROJECTS

The Institut Pasteur (Paris) and the Institut Pasteur International Network have been extremely active worldwide in responding with science to the pandemic caused by the SARS-CoV-2 coronavirus, responsible for Covid-19 disease.

ALL OUR COVID-19 NEWS 

Here are the news, press releases and videos from the Institut Pasteur (Paris), which was mobilized as soon as the first cases were announced, following the declaration of the epidemic by the Chinese authorities.

Le SARS-CoV-2 détourne les nanotubes reliant les neurones afin de les infecter
2022.07.21
COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both during the acute phase of the disease and over the long term with "long COVID" syndrome. But the way in which the infection reaches the brain was previously unknown. Scientists from Institut Pasteur and CNRS laboratories have used state-of-the-art electron microscopy approaches to demonstrate that SARS-CoV-2 hijacks nanotubes, tiny bridges that link infected cells with neurons.
2022.06.15
Although the different SARS-CoV-2 variants currently in circulation are undoubtedly less severe in vaccinated individuals in the general population, immunocompromised people are at greater risk of developing severe forms of COVID-19. Monoclonal antibodies currently offer the best approach, both as a preventive and curative treatment for these patients. Scientists from the Institut Pasteur and Inserm identified two potent neutralizing antibodies from convalescent COVID-19 individuals that proved effective against SARS-CoV-2 variants of concern.
2021.11.18
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among immunocompromised people, particularly in solid organ transplant recipients and patients with malignant hemopathies.
Crédit : Institut Pasteur. Image par Rémy Robinot, Mathieu Hubert, Vincent Michel, Olivier Schwartz et Lisa Chakrabarti, et colorisée par Jean Marc Panaud

Scientific Publications

 

 

  

Covid-19 disease fact sheet (novel coronavirus)

Fiche Maladie Covid-19 - Institut Pasteur

All the information about Covid-19 disease, caused by the SARS-CoV-2 coronavirus (cause, symptoms, transmission, prevention, treatment, etc.). The Covid-19 fact sheet is updated regularly.

 

 

FAKE NEWS

Coronavirus : attention aux fausses informations circulant sur les réseaux sociaux - Institut Pasteur

Coronavirus SARS-CoV-2 and Covid-19: beware of false information

 

Back to top